Antihypertensive therapy: Role of aldosterone antagonists

Current Pharmaceutical Design

Volumn 11, Issue 17, 2005, Pages 2235-2242

  Grandi, Anna Maria ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Aldosterone; Aldosterone antagonists; Canrenone; Diastolic function; Eplerenone; Hypertension; Myocardial hypertrophy; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CANRENOIC ACID; CANRENONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; NEW DRUG; SPIRONOLACTONE;

ALDOSTERONE RELEASE; ANTIHYPERTENSIVE THERAPY; ARTERIOSCLEROSIS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HORMONE ACTION; HORMONE INHIBITION; HUMAN; HYPERKALEMIA; IMPOTENCE; INFLAMMATION; MASTALGIA; MENSTRUATION DISORDER; NONHUMAN; ORGAN INJURY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; TREATMENT OUTCOME;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION;

EID: 21044442140     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612054367418     Document Type: Review

References (104)

1. Simpson SAS, Tait JF. Physicochemical methods of detection of a previously unidentified adrenal hormone. Mem Soc Endocrinol 1953; 2: 9-24.
2. Espiner E, Nichols M. The Renin Angiotensin System. London: Gower Medical Publishing 2002; 22.1-33.24.
3. Doggrell SA, Brown L. The spironolactone renaissance. Exp Opin Invest Drugs 2001; 10: 943-954.
4. Sica DA. Aldosterone receptor blockade: a therapy resurrected. Heart Dis 2003; 5: 85-88.
5. Williams JS, Williams GH. 50th Anniversary of aldosterone. J Clin Endocrinol Metab 2003; 88: 2364-2372.
6. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 1994; 269: 24316-24320.
7. Takeda Y, Miyamori I, Yoneda T, Hatakeyama H, Inaba S, Furukawa K, et al. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1996; 81: 2797-2800.
8. Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foucking MF, Gomez-Sanchez EP. Aldosterone biosynthesis in the rat brain. Endocrinology 1997; 138: 3369-3373.
9. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al. Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem 1998; 273: 4883-4891
10. Takeda Y, Yoneda T, Demura M, Furukawa K, Miyamori I, Mabuchi H. Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. J Hypertens 2001; 19: 635-639.
11. Silvestre JS, Heymes C, Oubénaissa A, Robert V, Aupetit-Faisant B, Carayon A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999; 99: 2694-2701.
12. Patel PD, Sherman TJ, Goldman DJ, Watson SJ. Molecular cloning of a mineralocorticoid (type 1) receptor complementary DNA, from rat hippocampus. Mol Endocrinol 1989; 3: 1877-1885.
13. Lombes M, Alfaidy N, Eugene E, Lessana A, Barman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995; 92: 175-182.
14. Funder JW, Pearce PT, Smith R, Campbell J. Vascular type 1 aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 1989; 125: 2224-2226.
15. Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, et al. Vascular aldosterone in genetically hypertensive rats. Hypertension 1997; 29: 45-48.
16. Selye H. The general adaptation syndrome and the diseases of adaptation. J Clin Endocrinol 1946; 6: 117-230.
17. Young M, Fullerton MJ, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93: 2578-2583.
18. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.
19. Young M, Head G, Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol 1995; 269: E657-E662.
20. Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res 1997; 35: 138-147.
21. Brilla CG, Pick R, Tan LP, Janicki JS, Weber KT. Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res 1990; 67: 1355-1364.
22. Young MJ, Funder JW. The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol 1996; 271: E883-E888.
23. Delcayre C, Silvestre JS, Garnier A, Oubenaissa A, Cailmail S, Tatara E, et al. Cardiac aldosterone production and ventricular remodeling. Kidney Int 2000; 57: 1346-1351.
24. Brilla CG, Matsubara LS, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993; 71: 12A- 16A.
25. Lacolley P, Safar ME, Lucet B, Ledudal K, Labat C, Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 2001; 37: 662-667.
26. Nicoletti A, Heudes D, Hinglais N, Appay MD, Philippe M, Sassy-Prigent C, et al. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone. Hypertension 1995; 26: 101-111.
27. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier Jr CT. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-458.
28. Brown NJ, Nakamura S, Ma L-J, Nakamura I, Donnert E, Freeman M, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 2000; 58: 1219-1227.
29. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063-1068.
30. Rocha R, Chander PN, Zuckerman A, Stier CT. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33[part II]: 232-237.
31. Ikeda U, Kanbe T, Nakayama Y, Kawahara Y, Yokoyama M, Shimada K. Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 β. Eur J Pharmacol 1995; 290: 69-73
32. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension 1992; 20: 67-73.
33. Sun Y, Ratajska A, Zhou G, Weber KT. Angiotensin converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterore. J Lab Clin Med 1993; 122: 395-403.
34. Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovasc Res 1996; 32: 266-273.
35. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedaw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33: 981-986.
36. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26: 809-820.
37. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994; 28: 1863-1867.
38. Kohler E, Bertschin S, Woodtli T, Resink T, Erne P. Does aldosterone-induced cardiac fibrosis involve direct effects on cardiac fibroblasts? J Vasc Res 1996; 33: 315-326.
39. Rocha R, Rudolph AE, Friedrich GE, Nachowiak DA, Kekec BK, Blomme EAG, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002; 283: H1802-H1810.
40. Sun Y, Zhang J, Iu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 2002; 161: 1773-1781.
41. Gerling IC, Sun Y, Ahokas RA, Wodi LA, Bhattacharya SK, Warrinton KJ, et al. Aldosteronism: an immunostimulatory state precedes proinflammatory/fibrogenic cadiac phenotype. Am J Physiol Heart Circ Physiol 2003; 285: H813-H821.
42. Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI-1: implications for renal injury. J Nephrol 2002; 15: 230-235.
43. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennkee HG, Williams GH, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878.
44. Yalcin AU, Dincer M, Aslan V, Gulbas Z. Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 2002; 25: 260-264.
45. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836.
46. Feria I, Pichardo I, Juarez P, Ramirez V, Gonzalez MA, Uribe N, et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43-52.
47. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 2002; 40: 504-510.
48. Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 2000; 85: 336-344.
49. Loskutoff DJ, Quigley JP. PAI-1, fibrosis and the elusive provisional fibrin matrix. J Clin Invest 2000; 106: 1441-1443.
50. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 1997; 95: 1471-1478.
51. Napoli C, DiGregorio F, Leccese M, Abete P, Ambrosio G, Giusti R, et al. Evidence of exercise- induced myocardial ischemia in patients with primary aldosteronism: the Cross-sectional Primary Aldosteronism and Heart Italian Multicenter Study. J Invest Med 1999; 47: 212-221.
52. Halimi J-M, Mimram A. Albuminuria in untreated patients with primari aldosteronism or essential hypertension. J Hypertens 1995; 13: 1801-1802.
53. Takeda R, Matsubara T, Miyamori I, Hatakeyama H, Morise T, Research Committee of Disorders of Adrenal Hormones in Japan. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. J Endocrinol Invest 1995; 18: 370-373.
54. Nishimura M, Uzu T, Fuji T, Kuroda S, Nakamura S, Inenaga T, et al. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261-266.
55. Heitzer T, Schlinzig T, Krohn K, meinertz T, Munzefl T. Endothelial dysfunction, oxidative stress and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-2678.
56. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993; 21: 929-933.
57. Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997; 10: 1326-1334.
58. Duprez DA, DeBuyzere ML, Rietzschel ER, Taes Y, Clement DL, Morgan D, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-1376.
59. Muscholl MW, Schunkert H, Muders F, Elsner D, Kuch B, Hense HW, et al. Neurohumoral activity and left ventricular geometry in patients with essential hypertension. Am Heart J 1998; 135: 58-66.
60. Duprez DA, Bauwens FR, Buyzere ML, DeBacker TL, Kaufman JM, Houcke JV, et al. Influence of arterial pressure and aldosterone in left ventricular hypertrophy in moderate essential hypertension. Am J Cardiology 1993; 71: 17A-20A.
61. El-Gharbawy AH, Nadig VS, Kotchen JM, Grim CE, Sagar KB, Kaldunski M, et al. Arterial pressure, left ventricular mass and aldosterone inessential hypertension. Hhypertension 2001; 37: 845-850.
62. Fagard RH, Lijnen PJ, Petrov VV. Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension. J Human Hypertens 1998; 12: 195-202.
63. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-597.
64. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056-1064.
65. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 2003; 16: 781-788.
66. Lijnen PM, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982; 49: 1561-1563.
67. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001; 29: 13-21.
68. Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33.
69. Pitt B, Zarmad F, Remme WJ, Cody R, Castaigne A, Perez A, et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709-717.
70. Zannad F, Alla F, Dousset B, Perez A, Pitt B, RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study. Circulation 2000; 102: 2700-2706.
71. Mantero F, Lucarelli G. Aldosterone antagonists in hypertension and heart failure. Ann Endocrinol 2000; 61: 52-60.
72. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenno H, Schenkel L, et al. Three new epoxyspironolactone derivative: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240: 650-656.
73. Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 2002; 15: 709-716.
74. Brown NJ. Eplerenone. Cardiovascular protection. Circulation 2003; 107: 2512-2518.
75. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60: 820-825.
76. Epstein M, Buckalew V, Martinez F, Altamisano J, Roniker B, Kleiman J, et al. Antiproteinuric efficacy of eplerenone, enalapril and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria. Am J Hypertens 2002; 15: 24A (abstract).
77. Young Jr WF. Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology 2003; 144: 2208-2213.
78. Flack J, Oparil S, Pratt JH, Roniker B, Garthwaite S, Kleiman JH, et al. Efficacy and tolerability of eplerenone and losartan in hypertensive black patients and white patients. J Am Coll Cardiol 2003; 41: 1148-1155.
79. White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021-1026.
80. Burgess E, Niegowksa J, Tan KW, Kipnes MS, Roniker B, Patrick JL, et al. Antihypertensive effects of eplerenone and enalapril in patients with essential hypertension. Am J Hypertens 2002; 15: OR-51.
81. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002; 40: 117-123.
82. Diez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation 1995; 91: 1450-1456.
83. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98: 535-540.
84. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 2000; 15: 264-272.
85. Brilla CG, Janicki JS, Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension: role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 1991; 69: 107-115.
86. Fouad FM, Slominski M, Tarazi RC. Left ventricular diastolic function in hypertension: relation to left ventricular mass and systolic function. J Am Coll Cardiol 1984; 3: 1500-1506.
87. Koren MJ, Devereux RB, Casale PN, savage DD, Laragh JM. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-352.
88. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1513.
89. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-46.
90. Grandi AM, Venco A, Bertolini A, Pantaleo P, Corbellino D Perani G, et al. Left ventricular function after reversal of myocardial hypertrophy in systemic hypertension and response to acute increase of afterload by cold pressor test. Am J Cardiol 1992; 69: 1439-1441.
91. Grandi AM, Bignotti M, Gaudio G, Zanzi P, Guasti L, Venco A. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine. J Cardiovasc Pharmacol 1995; 26: 737-741.
92. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388-1393.
93. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trail against atenolol. Lancet 2002; 359: 1004-1010.
94. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999; 22: 17-22.
95. Sato A, Takane H, Saruta T. High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients. Hypertens Res 2001; 24: 99-104.
96. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res 2002; 25: 837-842.
97. Grandi AM, Imperiale D, Santillo R, Barlocco E, Bertolini A, Guasti L, et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40: 647-652.
98. Upton MT, Gibson DG. The study of left ventricular function from digitized echocardiograms. Prog Cardiovasc Dis 1978; 20: 359-384
99. Lee CH, Hogan JC, Gibson DG. Diastolic disease in left ventricular hypertrophy: comparison of M-mode and Doppler echocardiography for the assessment of rapid ventricular filling. Br Heart J 1991; 65: 194-200.
100. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalapril and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. The 4E-Left Ventricular Hypertrophy Study. Circulation 2003; 108: 1831-8138.
101. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
102. Lombardi F, Terranova P. Hypertension and concurrent arrhythmias. Curr Pharm Design 2003; 9(21): 1703-13.
103. McMahon EG. Eplerenone, a new selective aldosterone blocker. Curr Pharm Design 2003; 9(13): 1065-75.
104. Nadar S, Lip GY. The prothrombotic state in hypertension and the effects of antihypertensive treatment. Curr Pharm Design 2003; 9(21): 1715-32.